

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>McDearis Kevin</u> <hr/> (Last) (First) (Middle) <u>65 FAIRCHILD STREET</u> <hr/> (Street) <u>CHARLESTON SC 29492</u> <hr/> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>12/09/2020</u>	3. Issuer Name and Ticker or Trading Symbol <u>BLACKBAUD INC [ BLKB ]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input type="checkbox"/> 10% Owner <input type="checkbox"/> <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>Chief Products Officer</u>	5. If Amendment, Date of Original Filed (Month/Day/Year)  6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
<u>Common Stock</u>	<u>57,910</u>	<u>D</u>	

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			

Explanation of Responses:

**Remarks:**

See Exhibit 99.1.

/s/ S. Halle Vakani,  
Attorney-in-Fact

01/11/2021

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

Known all by these presents, that the undersigned hereby constitutes and appoints each of Anthony Boor, Jon Olson, Donald R. Reynolds and S. Halle Vakani, and each of them acting alone, signing singly, the undersigned's true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer, director and/or 10% or more stockholder of Blackbaud, Inc. (the "Company"), Forms ID, 3, 4, 5, and Update Passphrase Acknowledgement (and any amendments thereto) in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended (the "1934 Act") and Schedules 13D and/or Schedules 13G (and any amendments thereto) in accordance with the 1934 Act, and the rules promulgated thereunder; (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form ID, 3, 4, 5, and Update Passphrase Acknowledgement and Schedules 13D and/or Schedules 13G (and any amendments thereto) and to file timely such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and (3) take any other action of any type whatsoever in connection with the foregoing which in the opinion of such attorney-in-fact may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming that all such attorneys-in-fact, or such attorneys-in-facts' substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the 1934 Act.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms ID, 3, 4 and 5 and Schedules 13D and Schedules 13G with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to each of the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 15th day of December 2020.

/s/ Kevin McDearis  
Kevin McDearis

Remarks:

Mr. McDearis' non-derivative securities owned beneficially comprise the following securities:

(a) 10,980 shares of restricted stock ("RS") were granted on August 11, 2014 and vested in 4 equal annual installments beginning on August 11, 2015 (4,586 of the resulting shares were withheld to satisfy tax liabilities incurred upon vesting and 6,394 have been sold); (b) 13,690 shares of RS were granted on February 13, 2015 and vested in 4 equal annual installments beginning on February 13, 2016 (5,785 of the resulting shares were withheld to satisfy tax liabilities incurred upon vesting and 7,905 have been sold); (c) 10,980 performance restricted stock units ("PRSUs") were earned on August 11, 2015 upon the vesting of a percentage of PRSUs granted August 11, 2014 upon the Issuer's achievement of performance goals for the period ended December 31, 2014 (4,817 of the resulting shares were withheld to satisfy tax liabilities incurred upon vesting and 4,270 have been sold); (d) 20,600 shares of RS were granted on February 11, 2016 and vested in 4 equal annual installments beginning on February 11, 2017 of which 1,102 shares of vested RS are held (8,297 of the resulting shares were withheld to satisfy tax liabilities incurred upon vesting and 11,201 have been sold); (e) 13,689 PRSUs were earned on February 13, 2016 upon the vesting of a percentage of PRSUs granted February 13, 2015 upon the Issuer's achievement of performance goals for the period ended December 31, 2015 (5,917 of the resulting shares were withheld to satisfy tax liabilities incurred upon vesting and 5,894 have been sold); (f) 15,124 shares of RS were granted on February 14, 2017 vesting in 4 equal annual installments beginning on February 14, 2018 (3/4 of the resulting shares are vested, of which 5,259 of the resulting shares were withheld to satisfy tax liabilities incurred upon vesting and 6,084 have been sold); (g) 20,600 PRSUs were earned on February 14, 2017 upon the vesting of a percentage of PRSUs granted February 11, 2016 upon the Issuer's achievement of performance goals for the period ended December 31, 2016 (7,894 of the resulting shares were withheld to satisfy tax liabilities incurred upon vesting and 7,401 have been sold); (h) 10,551 shares of RS were granted on February 12, 2018 vesting in 4 equal annual installments beginning on February 12, 2019 (1/2 of the resulting shares are vested, of which 2,420 of the resulting shares were withheld to satisfy tax liabilities incurred upon vesting and 2,855 have been sold); (i) 13,060 PRSUs were earned on February 14, 2018 upon the vesting of a percentage of PRSUs granted February 14, 2017 upon the Issuer's achievement of performance goals for the period ended December 31, 2017 (6,055 of the resulting shares were withheld to satisfy tax liabilities incurred upon vesting and 5,855 have been sold); (j) 6,681 PRSUs were earned on February 12, 2019 upon the vesting of a percentage of PRSUs granted February 12, 2018 upon the Issuer's achievement of performance goals for the period ended December 31, 2018 (2/3 of the resulting shares are vested, of which 2,043 of the resulting shares were withheld to satisfy tax liabilities incurred upon vesting, 2,411 have been sold and the remaining shares will vest on February 12, 2021); (k) 15,235 shares of RS were granted on February 12, 2019 vesting in 4 equal annual installments beginning February 12, 2020 (1/4 of the resulting shares are vested, of which 1,727 of the resulting shares were withheld to satisfy tax liabilities incurred upon vesting and 2,081 have been sold); (l) 16,639 PRSUs were earned on February 12, 2020 upon the vesting of a percentage of PRSUs granted February 12, 2019 upon the Issuer's achievement of performance goals for the period ended December 31, 2019 (1/3 of the resulting shares are vested, of which 2,572 of the resulting shares were withheld to satisfy tax liabilities incurred upon vesting, 2,975 have been sold, and the remaining shares will vest in two equal annual installments beginning on February 12, 2021); (m) 12,530 shares of RS were granted on February 12, 2020 vesting in 4 equal annual installments beginning on February 12, 2021; and (n) 248 restricted stock units ("RSUs") were granted on May 1, 2020 and will vest in full on May 1, 2021.

The vesting of all RSUs are subject to the Reporting Person's continued employment.